# Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity

> **NCT04702906** · NA · UNKNOWN · sponsor: **Tanta University** · enrollment: 40 (estimated)

## Conditions studied

- Aluminum Phosphide Poisoning

## Interventions

- **OTHER:** standard treatment
- **DRUG:** trimetazidine hydrochloride "metacardia" ® 20 mg tablet

## Key facts

- **NCT ID:** NCT04702906
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02
- **Primary completion:** 2021-06
- **Final completion:** 2021-07
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702906, "Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04702906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*